Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
The Pharma Data
JANUARY 17, 2021
“This marks another significant milestone as we continue to leverage our polypeptide nano-particle technology for siRNA drug delivery to advance our pipeline of oncology therapeutic candidates,” said Patrick Lu , Ph.D., 1 and COX-2 gene expression. the founder, President and CEO of Sirnaomics.
Let's personalize your content